Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy (EPZSwitch)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01608269
Recruitment Status : Completed
First Posted : May 31, 2012
Last Update Posted : April 28, 2017
Information provided by (Responsible Party):
Therapeutic Concepts

Brief Summary:
The purpose of this study is to assess the safety, tolerability, and antivira activity of Epzicom in virologically controlled HIV subjects.

Condition or disease Intervention/treatment Phase
HiV1- Positive Drug: Abacavir/Lamivudine Phase 4

Detailed Description:
Utilizing the ABC/3TC FDC tablets as the NRTI backbone, this open label study will compare the safety and efficacy of ABC/3TC when used as replacement for subjects with suboptimal CD4- cells count who are receiving TDF/FTC. TYhis study will be conducted for 48 weeks in HIV infected, HLA*B5701 begative subjects who were initially suppressed on a HAART regiment that includes TDF/FTC QD.

Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 30 participants
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Nucleoside Switch Pilot for Virologically Controlled HIV Subjects With Decreasing CD4 Cells Who Have Received TDF-based ARV Therapy
Study Start Date : November 2010
Actual Primary Completion Date : October 2012
Actual Study Completion Date : October 2012

Resource links provided by the National Library of Medicine

MedlinePlus related topics: HIV/AIDS

Arm Intervention/treatment
ABC/3TC (Epzicom), NRTI Drug: Abacavir/Lamivudine
one tablet once a day
Other Name: ABC/3TC

Primary Outcome Measures :
  1. Efficacy. [ Time Frame: 1 years ]
    Proportion of patients with CD4 changes from baseline at week 24 and 48. Proportion of patients with plasma HIV-1 RNA <75 copies/mL at week 24 and 48

Secondary Outcome Measures :
  1. Safety [ Time Frame: 1 year ]
    Adverse events and treatment limiting toxicities at all time points.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Ages Eligible for Study:   18 Years to 75 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • HIV-1 RNA ≤ 50 copies/mL by HIV-1 Ultrasensitive RNA, Quantitative.
  • Treatment experienced subjects on virologically stable HAART regimen containing tenofovir-emtricitabine or tenofovir-lamivudine.
  • Subject with CD4 cells that do not increase by 15% and/or that decrease by 15% over previous 12 months period.

    -≥ 18 years of age

  • Cognitive ability to understand and provide written informed consent and willingness to participate in and comply with the study protocol
  • Less than 7 days of prior ART with any licensed or investigational compound
  • Patient does not currently have or has not been treated for an active opportunistic infection (OI) consistent with CDC definition (Appendix C) within 30 days of screening
  • Vital signs, physical examination and laboratory results do not exhibit evidence of acute illness
  • A female is eligible to enter and participate in this study if she is of:
  • Non-childbearing potential (i.e., physiologically incapable of becoming pregnant, including any female who is post-menopausal) or
  • Child-bearing potential, has a negative serum pregnancy test at screen, and agrees to one of the following:
  • Complete abstinence from intercourse from 2 weeks prior to administration of the study drug, throughout the study, and for at least 2 weeks after completion or premature discontinuation from the study to account for elimination of the investigational drug. Should a patient decide to become sexually active during the course of the study, she must be counseled and be willing to use one of the birth control methods listed below:
  • Double barrier method (male condom/spermicide, male condom/diaphragm, diaphragm/spermicide)
  • Any intrauterine device (IUD) with published data showing that the expected failure rate is <1% per year (not all IUDs meet this criterion)
  • Sterilization (female patient or male partner of female patient)
  • Any other methods with published data showing that the lowest expected failure rate for that method is <1% per year.

Exclusion Criteria:

  • Patient with active AIDS-defining opportunistic infection or disease according to the 1993 CDC AIDS surveillance definition (Clinical Category C) in the 30 days prior to baseline and that, in the opinion of the investigator, would preclude the patient from participating in the study (See Appendix C).
  • Patient who are HLA B5701 Positive
  • Patient who are determined to have ≥2 thymidine analog mutations to RT
  • History of active substance abuse, excluding cannabis, or psychiatric illness that, in the opinion of the investigator, would preclude compliance with protocol, dosing schedule and assessments.
  • Patient is either pregnant at time of screening evaluation or breast-feeding.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01608269

United States, Texas
Therapeutic Concepts, PA
Houston, Texas, United States, 77004
Sponsors and Collaborators
Therapeutic Concepts

Responsible Party: Therapeutic Concepts Identifier: NCT01608269     History of Changes
Other Study ID Numbers: 101-002
First Posted: May 31, 2012    Key Record Dates
Last Update Posted: April 28, 2017
Last Verified: May 2012

Additional relevant MeSH terms:
Reverse Transcriptase Inhibitors
Nucleic Acid Synthesis Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Anti-Retroviral Agents
Antiviral Agents
Anti-Infective Agents
Anti-HIV Agents